Achieving Good Metabolic Control Without Weight Gain with the Systematic Use of GLP-1-RAs and SGLT-2 Inhibitors in Type 2 Diabetes: A Machine-learning Projection Using Data from Clinical Practice.

Artificial intelligence what-if projection HbA(1c) and weight control Real-life therapeutic inertia Use of SGLT2i and GLP1-RA

Journal

Clinical therapeutics
ISSN: 1879-114X
Titre abrégé: Clin Ther
Pays: United States
ID NLM: 7706726

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 30 01 2023
revised: 18 05 2023
accepted: 07 06 2023
pubmed: 15 7 2023
medline: 15 7 2023
entrez: 14 7 2023
Statut: ppublish

Résumé

Recently, the 2022 American Diabetes Association and European Association for the Study of Diabetes (ADA-EASD) consensus report stressed the importance of weight control in the management of patients with type 2 diabetes; weight control should be a primary target of therapy. This retrospective analysis evaluated, through an artificial-intelligence (AI) projection of data from the AMD Annals database-a huge collection of most Italian diabetology medical records covering 15 years (2005-2019)-the potential effects of the extended use of sodium-glucose co-transporter 2 inhibitors (SGLT-2is) and of glucose-like peptide 1 receptor antagonists (GLP-1-RAs) on HbA Data from 4,927,548 visits in 558,097 patients were retrospectively extracted using these exclusion criteria: type 1 diabetes, pregnancy, age >75 years, dialysis, and lack of data on HbA The first query of the AI analysis showed a great improvement in achievement of the combined goal: 38.8% with prescribing in clinical practice versus 66.5% with prescribing in the "what-if" simulation. Addressing persistence at 18 months after the initial achievement of the combined goal, the simulation showed a potential better performance of SGLT-2is and GLP-1-RAs with respect to each antidiabetic pharmacologic class or combination considered. AI appears potentially useful in the analysis of a great amount of data, such as that derived from the AMD Annals. In the present study, an LLM analysis revealed a great potential improvement in achieving metabolic targets with SGLT-2i and GLP-1-RA utilization. These results underscore the importance of early, timely, and extended use of these new drugs.

Identifiants

pubmed: 37451913
pii: S0149-2918(23)00201-1
doi: 10.1016/j.clinthera.2023.06.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

754-761

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have indicated that they have no conflicts of interest with regard to the content of this article.

Auteurs

Carlo Bruno Giorda (CB)

Metabolism and Diabetes Unit, ASL, Torino, Italy. Electronic address: carlogiordaposta@gmail.com.

Antonio Rossi (A)

Metabolism and Diabetes Unit, ASST Fatebenefratelli, Milan, Italy.

Fabio Baccetti (F)

ASL Nordovest Toscana, Massa Carrara, Italy.

Rita Zilich (R)

Mix-x Partner, Milan, Italy.

Francesco Romeo (F)

Metabolism and Diabetes Unit, ASL, Torino, Italy.

Nreu Besmir (N)

Diabetes Unit, Careggi Hospital, Firenze, Italy.

Graziano Di Cianni (G)

Diabetes and Metabolic Diseases Unit, Health Local Unit Nord-West Tuscany, Livorno Hospital, Italy.

Giacomo Guaita (G)

Diabetes and Endocrinology Unit, ASLSULCIS Carbonia-Iglesias, Italy.

Lelio Morviducci (L)

Diabetes and dietetics Unit, Santo Spirito Hospital, ASL Rome, Italy.

Marco Muselli (M)

Rulex Innovation Labs, Genova, Italy; Institute of Electronics, Computer and Telecommunication Engineering, National Research Council of Italy, Genoa, Italy.

Alessandro Ozzello (A)

AIAMD National Group, Bruino, Italy.

Federico Pisani (F)

artificial intelligence consultancy, Ivrea, Italy.

Paola Ponzani (P)

Metabolism and Diabetes Unit, ASL4, Chiavari, Italy.

Pierluigi Santin (P)

Data Scientist Deimos, Udine, Italy.

Damiano Verda (D)

Rulex Innovation Labs, Genova, Italy.

Nicoletta Musacchio (N)

AIAMD National Group, Bruino, Italy.

Classifications MeSH